These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 33108882)
1. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects. Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882 [TBL] [Abstract][Full Text] [Related]
3. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783 [TBL] [Abstract][Full Text] [Related]
4. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P Front Immunol; 2021; 12():690467. PubMed ID: 34367149 [TBL] [Abstract][Full Text] [Related]
5. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ploessl C; Pan A; Maples KT; Lowe DK Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818 [TBL] [Abstract][Full Text] [Related]
6. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance. Barone G; Barry A; Bautista F; Brichard B; Defachelles AS; Herd F; Manzitti C; Reinhardt D; Rubio PM; Wieczorek A; van Noesel MM Paediatr Drugs; 2021 Nov; 23(6):537-548. PubMed ID: 34541620 [TBL] [Abstract][Full Text] [Related]
7. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava. Achbergerová M; Hederová S; Hrašková A; Kolenová A Medicine (Baltimore); 2022 Jan; 101(4):e28716. PubMed ID: 35089239 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. Mastrangelo S; Rivetti S; Triarico S; Romano A; Attinà G; Maurizi P; Ruggiero A Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884452 [TBL] [Abstract][Full Text] [Related]
13. Dinutuximab for the treatment of pediatric patients with neuroblastoma. Greenwood K; Foster JH Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760 [TBL] [Abstract][Full Text] [Related]
14. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Mora J Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530 [TBL] [Abstract][Full Text] [Related]
15. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106 [TBL] [Abstract][Full Text] [Related]
16. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Greenwood KL; Foster JH Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831 [TBL] [Abstract][Full Text] [Related]
17. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555 [TBL] [Abstract][Full Text] [Related]
19. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552 [TBL] [Abstract][Full Text] [Related]
20. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma. Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]